CHRS is set for an enormous 2023
Small-cap biotech with small float, high institutional ownership, moderately high short interest, healthy balance sheet.
Products on the market are a neulasta biosimilar and a lucentis biosimilar, which just launched in October. Humira biosimilar approved and set for July 1 launch. Approval of our version of neulasta on-pro injection device imminent. Approval of Tori, cornerstone immunoncology drug, likely imminent as China reopens, allowing inspection of manufacturing plant.
How many other $600 million companies will have five high-value products on the market this summer?
Leave a Reply